Regeneron Pharmaceuticals' (REGN) stock is trading in the red premarket on Thursday after net product sales ... COVID‑19 antibody therapy REGEN-COV saw a decline of -3.52% Y/Y to $613.2M in ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. ... (REGN) : Free Stock Analysis Report.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%. The stock has underperformed the sector and the S&P 500 Index ...

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD ...

Regeneron Pharmaceuticals, Inc. ... REGN stock declined 29.8%, compared to the Health Care Select Sector SPDR Fund’s 10.9% decline during the same time frame.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%. The stock has outperformed the sector during this timeframe but ...

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.